How to Cure Cough Normally

ORGANIC CHEMISTRY SELECT

A cough is a response of the physique to irritants affecting the respiratory system. It is normally outlined as the unexpected act of expelling air from the lungs with a sharp sound. It can be a deliberate or involuntary act. Generally, it is the body&rsquos way of expelling bacteria and should not be suppressed

There are 2 significant varieties of coughs:

1. Dry or unproductive cough &ndash this sort of cough does not deliver up any mucus or phlegm, it could build in the direction of the end of an infection or be brought on by gentle irritants like dust, smoke, and so on.
2. Successful cough &ndash unlike the dry cough, this cough provides up with it mucus and/or phlegm, brings about might be infection, viral, use of tobacco, etc.

Aside from these two broad types a cough may possibly also be described as:

1. Acute &ndash that lasts for practically 3…

View original post 817 more words

Advertisements

VIVUS Announces SPEDRA (avanafil) Approval in Europe

New Drug Approvals

AVANAFIL

June 26, 2013

VIVUS, Inc. today announced that the European Commission (EC) has adopted the implementing decision granting marketing authorization for SPEDRA(TM) (avanafil) for the treatment of erectile dysfunction (ED) in the European Union (EU). The approval of the marketing authorization application (MAA) by the EC follows the positive recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2013.
SPEDRA, a PDE5 inhibitor, is the first new chemical entity (NCE) approved for ED in over a decade. The global market for ED therapies was approximately $5.5 billion in 2012.

About Avanafil

STENDRA, or avanafil, is approved by the FDA for the treatment of erectile dysfunction, or ED, in the U.S. VIVUS, through collaboration arrangements with third parties, intends to market and sell STENDRA in the U.S. and under the trade name SPEDRA in the EU and other territories outside the U.S. Avanafil…

View original post 86 more words

TOSEDOSTAT CLINICAL TRIALS

New Drug Approvals

Tosedostat

Benzeneacetic acid, α-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-, cyclopentyl ester, (αS)-

Cyclopentyl (2S)-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)acetate

[238750-77-1]

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the “FDA”) partial clinical hold on tosedostat (IND 075503), the Company’s aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI’s primary development programs are the ongoing Phase 3 trial of pacritinib, the Company’s JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI^®(pixantrone).

http://www.heraldonline.com/2013/06/25/4972677/cti-issues-statement-regarding.html

View original post

Date rape drug sensor

New Drug Approvals

 

gamma-butyrolactone

The first fluorescent sensor for known date rape drug gamma-butyrolactone (GBL) has been developed in Singapore. It emits orange fluorescence in alcoholic drinks containing GBL when irradiated with a green laser.

Gamma-butyrolactone (GBL) is a readily available industrial solvent that is often used as a date rape drug. There are several detection kits that can show if a drink has been spiked with drugs like gamma-hydroxybutyric acid (GHB) and ketamine but there are no commercially available sensors to detect GBL.

http://www.rsc.org/chemistryworld/2013/06/date-rape-drug-sensor-gamma-butyrolactone

read also

Fernando Patolsky and Michael Ioffe of Tel Aviv University developed a sensor that, when dipped into a drink, will instantly detect the presence of a drug such as GHB, ketamine, or Rohypnol.

Date rape drug sensor

more info on other drug

Ketamine

Predatory drugs or date rape drugs are responsible for the creation of the most dangerous and pathologic environment that exists around drug use…

View original post 641 more words

Catalytic deoxygenation of microalgae oil to green hydrocarbons

Green Chemistry International

Green Chem., 2013, 15,1720-1739
DOI: 10.1039/C3GC40558C, Critical Review

Chen Zhao, a, Thomas Bruck, b, Johannes A. Lercher, ac,

Department of Chemistry and Catalysis Research Center, Technische Universität München, Garching D-85747, Germany

^b

Industrial Biocatalysis, Department of Chemistry, Technische Universität München, Garching D-85747, Germany

^c

Institute for Integrated Catalysis, Pacific Northwest National Laboratory, 902 Battelle Boulevard, Richland, USA

Catalytic routes for conversion of microalgae oil to green hydrocarbons.

Catalytic deoxygenation of microalgae oil to green hydrocarbons

Microalgae are high potential raw biomass material for triglyceride feedstock, due to their high oil content and rapid growth rate, and because algae cultivation does not compete with edible food on arable land. This review addresses first the microalgae cultivation with an overview of the productivity and growth of microalgae, the recovery of lipids from the microalgae, and chemical compositions of microalgae biomass and microalgal oil. Second, three basic approaches are discussed…

View original post 49 more words

TOSEDOSTAT CLINICAL TRIALS

New Drug Approvals

Tosedostat

Benzeneacetic acid, α-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-, cyclopentyl ester, (αS)-

Cyclopentyl (2S)-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)acetate

[238750-77-1]

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the “FDA”) partial clinical hold on tosedostat (IND 075503), the Company’s aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI’s primary development programs are the ongoing Phase 3 trial of pacritinib, the Company’s JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI^®(pixantrone).

http://www.heraldonline.com/2013/06/25/4972677/cti-issues-statement-regarding.html

View original post

VIVUS Announces SPEDRA (avanafil) Approval in Europe

New Drug Approvals

AVANAFIL

June 26, 2013

VIVUS, Inc. today announced that the European Commission (EC) has adopted the implementing decision granting marketing authorization for SPEDRA(TM) (avanafil) for the treatment of erectile dysfunction (ED) in the European Union (EU). The approval of the marketing authorization application (MAA) by the EC follows the positive recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2013.
SPEDRA, a PDE5 inhibitor, is the first new chemical entity (NCE) approved for ED in over a decade. The global market for ED therapies was approximately $5.5 billion in 2012.

About Avanafil

STENDRA, or avanafil, is approved by the FDA for the treatment of erectile dysfunction, or ED, in the U.S. VIVUS, through collaboration arrangements with third parties, intends to market and sell STENDRA in the U.S. and under the trade name SPEDRA in the EU and other territories outside the U.S. Avanafil…

View original post 86 more words